Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | EGFRt/19-28z/IL-12 CAR-T cells |
Synonyms | |
Therapy Description |
Limited information is currently available on EGFRt/19-28z/IL-12 CAR-T cells, a putative IL-12 expressing CAR T cell therapy (Apr 2024). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
EGFRt/19-28z/IL-12 CAR-T cells | Limited information is currently available on EGFRt/19-28z/IL-12 CAR-T cells, a putative IL-12 expressing CAR T cell therapy (Apr 2024). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT06343376 | Phase I | EGFRt/19-28z/IL-12 CAR-T cells Cyclophosphamide + Fludarabine | Genetically Engineered Cells (EGFRt/19-28z/IL-12 CAR T Cells) for the Treatment of Relapsed or Refractory CD19+ Hematologic Malignancies | Recruiting | USA | 0 |